LOS ANGELES, June 4, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ: OCGN) for for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 8, 2020 and April 1, 2024, inclusive (the "Class Period"), are encou ...

NEW YORK, June 3, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ocugen, Inc. (NASDAQ: OCGN) between May 8, 2020 and April 1, 2024, both dates inclusive (the "Class Period"), of the important June 10, 2024 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Ocugen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs throu ...

ATLANTA, June 03, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN). The lawsuit alleges that Defendants made materially false and misleading statements and/or failed to disclose material adverse information regarding the Company's business, operations, and prospects, including allegations that: (1) Ocugen's financial statements from May 8, 2020 to the present were materially misstated; and (2) Ocugen did not have adequ ...

MALVERN, Pa., May 31, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced a positive outcome of the Data and Safety Monitoring Board (DSMB) Review for its Phase 1/2 ArMaDa clinical trial for OCU410 (AAV5-hRORA)—a modifier gene therapy candidate being developed for geographic atrophy (GA), an advanced stage of dry age-related macular degeneration ...

NEW YORK, May 30, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Ocugen and certain of its officers and/or d ...

MALVERN, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company will present at the 2024 BIO International Convention taking place in San Diego, CA from June 3 – 6, 2024. During the conference, Ocugen's leadership team will host meetings with potential partners and pharmaceutical executives to explore opportunities fo ...

MALVERN, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company will present at the 2024 BIO International Convention taking place in San Diego, CA from June 3 – 6, 2024. During the conference, Ocugen's leadership team will host meetings with potential partners and pharmaceutical executives to explore opportunities fo ...

MALVERN, Pa., May 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced its expected upcoming inclusion in the Russell 3000® Index, according to preliminary Russell reconstruction information posted on the FTSE Russell website. The newly reconstructed index will take effect after the market closes on June 28, 2024. "Inclusion of Ocugen to the ...

MALVERN, Pa., May 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced its expected upcoming inclusion in the Russell 3000® Index, according to preliminary Russell reconstruction information posted on the FTSE Russell website. The newly reconstructed index will take effect after the market closes on June 28, 2024. "Inclusion of Ocugen to the ...

Core Viewpoint - Ocugen has experienced a significant share price increase of 229% since January, attributed to clinical progress, but remains a high-risk investment due to various uncertainties and challenges in its pipeline [1]. Group 1: Pipeline and Market Potential - Ocugen is focusing on several candidates in late-stage development, with OCU400 being the lead asset aimed at treating retinitis pigmentosa (RP), a rare genetic eye disease [2][3]. - If approved, OCU400 could be a one-time curative gene therapy, with Ocugen projecting potential revenue of $30 billion to $47 billion in the five years post-approval, expected in 2026 [4]. - The company is also developing OCU410 for dry age-related macular degeneration, with projected sales of $75 billion in the first five years, currently in phase 1/2 testing [5]. Group 2: Risks and Market Response - Despite promising projections, the market has not adjusted Ocugen's share price significantly due to the high-risk nature of these estimates, which are not risk-adjusted [6]. - Ocugen faces substantial risks, including the possibility that OCU400 may not be effective in its late-stage trial, which could lead to a drastic decline in share value [7]. - The absence of larger biotech partners for Ocugen's programs raises concerns about the attractiveness of its products and the company's ability to navigate clinical and regulatory challenges [10]. Group 3: Financial Situation - As of the first quarter, Ocugen had $26.4 million in cash and equivalents, which is insufficient to sustain its ongoing clinical studies [11]. - The company may need to pursue additional funding soon, potentially through a secondary stock offering or debt issuance, which could negatively impact its share price [12].